Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADOPT: Adaptive Organoid-Based Precision Therapy in Pancreatic Cancer
NCT06813079Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Apr 2025
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Nucleic Acid-Directed Small Molecules, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of cobimetinib, ponatinib, brigatinib, colchicine, selinexor in pancreatic ductal adenocarcinoma (PDAC), sponsored by University Health Network. Started Apr 2025; status: recruiting.
02
Drugs
cobimetinibponatinibbrigatinibcolchicineselinexor
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06813079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06813079.